8-K: Silo Pharma Secures $2.5M in Direct Offering

Silo Pharma, Inc. has closed a $2.5 million registered direct offering of common stock and warrants to institutional investors for working capital and general corporate purposes.

Summary

• Silo Pharma, Inc. entered into a securities purchase agreement with institutional investors on September 29, 2025.
• The company sold 2,857,143 shares of common stock at a purchase price of $0.875 per share.
• Concurrently, unregistered warrants to purchase 2,857,143 shares of common stock were issued, with an exercise price of $0.75 per share.
• The warrants are immediately exercisable and expire five years from the effective date of a resale registration statement for the underlying shares.
• The offering generated approximately $2.5 million in gross proceeds, before deducting placement agent fees and other offering expenses.
• Net proceeds will be used for working capital and general corporate purposes.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a 7.5% cash fee and a 1.0% management fee of gross proceeds, plus warrants to purchase 214,285 shares at $1.0938 per share.
• The company is prohibited from issuing additional common stock or equivalents for 30 days post-closing and from Variable Rate Transactions for one year, with specific exceptions.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for a developmental-stage company, which is positive for its operations. However, the significant dilution from shares and warrants, coupled with the relatively low offering price, indicates a moderate sentiment. The use of proceeds for general corporate purposes is standard but lacks specific, high-impact project allocation details.

Positives

• Secured $2.5 million in gross proceeds, strengthening the company's financial position for working capital and general corporate purposes.
• The offering was priced "at-the-market" under Nasdaq rules, indicating market acceptance at the time of pricing.
• The company has a shelf registration statement on Form S-3 already effective, facilitating the offering process.
• The company is actively pursuing development in therapeutic areas like PTSD, fibromyalgia, chronic pain, Alzheimer's, and multiple sclerosis, indicating ongoing R&D.

Negatives

• The issuance of 2,857,143 shares of common stock and warrants to purchase an equal number of shares will result in significant dilution for existing shareholders.
• Additional warrants were issued to the placement agent (214,285 shares), further contributing to potential future dilution.
• Placement agent fees and other offering expenses will reduce the net proceeds received by the company.
• The offering price of $0.875 per share is below the placement agent warrant exercise price of $1.0938, and the investor warrant exercise price of $0.75, suggesting the offering was done at a relatively low valuation.

Risks

• Future dilution from the exercise of warrants issued to institutional investors and the placement agent.
• The company is a developmental-stage biopharmaceutical company, implying inherent risks associated with drug development, clinical trials, and regulatory approvals.
• Reliance on the effectiveness of a future resale registration statement for the warrant shares, which could impact liquidity for warrant holders.
• The company's business includes "cryptocurrency treasury company" which introduces additional market volatility and regulatory risks not detailed in this filing but mentioned in the company description.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. It also plans to file a registration statement for the resale of warrant shares within 15 calendar days and use commercially reasonable efforts to make it effective within 75 calendar days.

Management Comments

• We intend to use the net proceeds from the Offering for working capital and other general corporate purposes.

Industry Context

This capital raise provides Silo Pharma with additional funding to advance its developmental-stage biopharmaceutical programs, which focus on underserved conditions like PTSD, fibromyalgia, chronic pain, Alzheimer's, and multiple sclerosis. The funding is crucial for R&D-intensive sectors like biopharmaceuticals, especially for companies with a diverse pipeline including psychedelic treatments, which often require substantial capital for preclinical and clinical development.

Comparison to Industry Standards

• The offering structure, a registered direct offering with concurrent private placement of warrants, is a common method for small-cap biopharmaceutical companies to raise capital efficiently, similar to offerings by companies like MindMed (MNMD) or Compass Pathways (CMPS) in the psychedelic-focused biopharma space, which frequently utilize such mechanisms to fund their R&D pipelines.
• The placement agent fees (7.5% cash + 1.0% management fee + warrants) are within the typical range for small-cap direct offerings, which can often be higher than for larger, more established companies due to perceived higher risk and smaller deal sizes.
• The beneficial ownership limitation (4.99% or 9.99%) is standard practice to prevent investors from triggering beneficial ownership reporting requirements under Section 13(d) of the Exchange Act, which is common in such private placements.

Stakeholder Impact

• Shareholders: Existing shareholders will experience dilution due to the issuance of new common stock and the potential exercise of warrants. The offering price of $0.875 per share is a reference point for valuation.
• Investors (Purchasers in Offering): These institutional investors acquire common stock and warrants, providing them with immediate equity and potential upside through warrant exercise.
• Placement Agent (H.C. Wainwright & Co., LLC): Benefits from significant fees (7.5% cash, 1.0% management) and warrants, indicating a substantial financial incentive for facilitating the offering.
• Employees: The capital raise provides funding for ongoing operations, potentially securing jobs and supporting R&D efforts.

Next Steps

• File a registration statement on Form S-3 (or other appropriate form) for the resale of the Warrant Shares within 15 calendar days of the Purchase Agreement date.
• Use commercially reasonable efforts to cause the resale registration statement to be declared effective by the SEC within 75 calendar days (or 90 days if subject to full review).
• Keep the resale registration statement effective until holders no longer own any Warrants or Warrant Shares.
• Continue to use net proceeds for working capital and general corporate purposes.

Key Dates

Recommendation

While the $2.5 million capital raise provides essential funding for Silo Pharma's ongoing biopharmaceutical development, the significant dilution from the issuance of new shares and warrants, coupled with the relatively low offering price, suggests a cautious approach. The company operates in a high-risk, developmental stage industry. The funding is for general corporate purposes, lacking specific high-impact project allocation. Investors should hold to monitor the progress of their therapeutic pipeline and the effective deployment of these funds, while being mindful of potential further dilution and the inherent risks of a biopharmaceutical company.

Keywords

Silo Pharma, SILO, Registered Direct Offering, Private Placement, Common Stock, Warrants, Capital Raise, Biopharmaceutical, Drug Development, Working Capital, SEC Filing, Nasdaq, PTSD, Fibromyalgia, Alzheimer's, Multiple Sclerosis